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Background: The impact of the age of first Plasmodium falciparum infection on the rate of acquisition of immunity to
malaria and on the immune correlates of protection has proven difficult to elucidate. A randomized, double-blind,
placebo-controlled trial using monthly chemoprophylaxis with sulphadoxine-pyrimethamine plus artesunate was
conducted to modify the age of first P. falciparum erythrocytic exposure in infancy and assess antibodies and
malaria risk over two years.
Methods: Participants (n = 349) were enrolled at birth to one of three groups: late exposure, early exposure and
control group, and were followed up for malaria morbidity and immunological analyses at birth, 2.5, 5.5, 10.5,
15 and 24 months of age. Total IgG, IgG subclasses and IgM responses to MSP-119, AMA-1, and EBA-175 were
measured by ELISA, and IgG against variant antigens on the surface of infected erythrocytes by flow cytometry.
Factors affecting antibody responses in relation to chemoprophylaxis and malaria incidence were evaluated.
Results: Generally, antibody responses did not vary significantly between exposure groups except for levels of
IgM to EBA-175, and seropositivity of IgG1 and IgG3 to MSP-119. Previous and current malaria infections were
strongly associated with increased IgG against MSP-119, EBA-175 and AMA-1 (p < 0.0001). After adjusting for
exposure, only higher levels of anti-EBA-175 IgG were significantly associated with reduced clinical malaria
incidence (IRR 0.67, p = 0.0178).
Conclusions: Overall, the age of first P. falciparum infection did not influence the magnitude and breadth of
IgG responses, but previous exposure was critical for antibody acquisition. IgG responses to EBA-175 were the
strongest correlate of protection against clinical malaria.
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Malaria is among the leading causes of morbidity and
death in children, despite being a preventable disease.
The World Health Organization estimates that 219 mil-
lion cases and 660,000 deaths occurred in 2010, with ap-
proximately 81 and 91%, respectively, being in sub-
Saharan Africa [1]. Under similar levels of exposure to
Plasmodium falciparum different individuals experience
different outcomes; while some may die of severe mal-
aria others may experience mild disease to asymptomatic
infection [2,3]. However, immunity to malaria is poorly
understood. The rate of its development is thought to be
associated with transmission intensity; it is both species
and stage-specific and is rarely sterile [4]. In endemic
areas, the acquisition of partial immunity to severe
forms of the disease is observed relatively early in life
[2], whereas immunity to parasitaemia and mild clinical
malaria appear to take longer to develop and may re-
quire repeated parasite exposure for maintenance [5,6].
Human host genetics, parasite genetic variability and
parasite-induced immunosuppression also influence the
acquisition of immunity [7,8].
In people living in endemic areas, malaria infection in-
duces strong humoral immune responses, involving pro-
duction of predominantly immunoglobulin (Ig) M and
IgG [9,10]. Cytophilic IgG isotypes, IgG1 and IgG3 are
known to cooperate with monocytes to inhibit parasite
growth in vitro by promoting phagocytosis of P. falcip-
arum-infected erythrocytes [3,9,11,12]. Passive transfer
of IgG from immune donors to non-immune children
demonstrated that antibodies can be protective by redu-
cing parasitaemia and clinical disease [13]. Parasite growth
inhibition by plasma has been demonstrated in vitro for
some blood stage antigens that are candidates for malaria
vaccines. First, the recombinant 62 kDa apical membrane
antigen-1 (AMA-1), involved in the re-orientation of mer-
ozoites prior to invasion of the erythrocyte [14]; second,
the erythrocyte binding antigen (EBA-175), a 175 kDa
protein assumed to bind glycophorin A (GpA) during in-
vasion [14,15]; and, third, the 195 kDa merozoite surface
protein-1 (MSP-119), the most abundant merozoite sur-
face protein, thought to be involved in the initial attach-
ment of the merozoite to the erythrocyte surface [14].
Sero-epidemiological studies in populations of endemic
areas have shown some evidences of the role of antibodies
to these antigens in protecting against malaria [16].
Variant surface antigens (VSA) expressed on the para-
sitized erythrocyte membrane are thought to induce pro-
tective responses to P. falciparum as well [17]. The
predominant VSA are encoded by ~60 var genes per
parasite genome [18]. The gene product, called P. falcip-
arum erythrocyte membrane protein 1 (PfEMP-1), is
highly variant and equipped with several binding sites
mediating adhesion of infected erythrocytes to vascularendothelium of capillaries and post-capillary venules
thus avoiding destruction in the spleen [18-21]. Follow-
ing acute disease, children develop specific immune re-
sponses to the repertoire of VSAs of the parasites that
cause the infection [5,6]. Anti-VSA antibodies carried by
the host at the time of disease impose a selection pres-
sure on the repertoire of VSAs expressed during an in-
fection [22].
Longitudinal studies in Indonesia [23] and Tanzania
[24,25] suggested that a more mature immune system
should acquire immunity against malaria more efficiently
than a developing immune system, and that the age of
first exposure to the parasite might influence the devel-
opment of immunity. However, the exact effect of age of
first exposure on the development of immunity was not
clear, and this is critical for preventing children from
avoidable life-threatening infections. Following conclu-
sions from these studies, it was hypothesized that expos-
ure to P. falciparum during the first six months of life
was not relevant for acquisition of immunity, whereas
exposure in the second six months could be critical for
acquisition of immunity, and conducted a clinical trial to
test this. The age of first exposure to P. falciparum
blood stage infection was controlled by chemoprophy-
laxis with sulphadoxine-pyrimethamine (SP) plus artesu-
nate (AS) during different periods of the first year of life
in Mozambican children who were then followed up to
24 months for clinical malaria [26]. The conclusion of
this trial was that after significantly interfering with ex-
posure during the first year of life, the age of first expos-
ure to malaria did not seem to affect the incidence of
clinical malaria in the second year. However it remains
to be established whether the intervention affected the
acquisition of antibody responses to antigens considered
to be targets of blood stage immunity.
A detailed assessment of antibody responses to MSP-
119, AMA-1, EBA-175 and VSA antigens was conducted
in the children participating in the clinical trial during
their first two years of life. Risk factors affecting antibody
levels were examined at five cross sectional visits and
upon P. falciparum infection and convalescence, and the
association between the magnitude and breadth of anti-
body response and subsequent incidence of malaria.
Methods
Study site and population
The study was conducted in the District of Manhiça
(Maputo Province) in Southern Mozambique, in the
neighbourhoods of Maragra and Maciana in the town of
Manhiça. Characteristics of the area have been described
elsewhere [27]. Briefly, transmission of P. falciparum
malaria is perennial with two well-demarked seasons, a
dry season (May-October) and a rainy season (November-
April). The entomological inoculation rate estimated in
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graphic surveillance system (DSS) that has been in place
since mid-1996 continuously monitored the residents.
Inhabitants are mostly subsistence farmers living in com-
pounds separated by garden plots and grazing land [26].
Study design
The study was a double-blind, randomized, placebo-
controlled trial, described in detail elsewhere [26].
Briefly, 391 HIV-negative pregnant women were invited
to have their infants participate in the trial. Forty-five
newborns were excluded from the study: ten with-
drawals, eight stillbirths, three deaths before inclusion,
one unknown and twenty three who did not meet inclu-
sion criteria (birth weight <2 kg, same gender twins,
congenital malformations or birth asphyxia). A total of
349 newborns and their mothers were enrolled in the
study and 287 children completed the two-year follow
up [26]. Eligible newborns were randomized to one of
three chemoprophylactic groups. The late exposure
group received monthly chemoprophylaxis with SP + AS
from 2.5 until 4.5 months of age and placebo from 5.5
to 9.5 months of age. The early exposure group received
placebo from 2.5 until 4.5 months of age and monthly
chemoprophylaxis from 5.5 to 9.5 months of age. The
control group received monthly placebo from 2.5 to
9.5 months of age. Given the relatively long half-life of
SP, it was assumed that the chemoprophylactic effect
lasted for at least one month after each administration.
One-and-a-half mL of capillary blood was collected for
serological and parasitological determinations at cross-
sectional visits (2.5, 5.5, 10.5, 15 and 24 months). Capillary
blood from the first acute malaria infection and at conva-
lescence, one month after the first malaria episode, was
also collected for serological and parasitological analyses.
Ethical clearance
Approval for the study was obtained from the National
Mozambican Ethics Review Committee (Ref 05/CNBS/05)
and the Hospital Clínic of Barcelona Ethics Review
Committee. Children were enrolled in the study after
their mothers gave a written informed consent.
Parasite isolates, in vitro culture and measurement of IgG
against VSA
In previous work by the same group, a panel of parasite
isolates (Moz2, R29, 3D7, ItG and EB8) was tested for
immunogenicity. The laboratory line (R29) was found to
be the most immunogenic in the study area [29,30].
Stocks of ring stage at 3% parasitaemia were prepared
from R29 P. falciparum parasite in vitro cultures. Para-
sites were cryopreserved by adding 1.7 volumes of gly-
cerolyte dropwise and at a continuous agitation, and
then kept at -80°C. For recovery, parasite aliquots werethawed using two sodium chloride thawing solutions
(0.2 V of 12% NaCl and 10 V of 1.6%; and washed with
RPMI incomplete media) following the protocol de-
scribed elsewhere [6]. Parasite culture to late trophozoite
was done using standard protocols [31].
The protocol for quantifying IgG against P. falciparum
VSA has been described elsewhere [6]. Briefly, 95 μL of
trophozoite-infected erythrocytes (T-iE) at 1% parasit-
aemia were sequentially exposed to 5 μL of plasma,
0.5 μL of polyclonal rabbit anti-human IgG (Dako,
Glostrup, Denmark) and 0.1 μL of a goat anti-rabbit IgG
antibody (Invitrogen, Molecular Probes, Carlsbad, USA)
together with 0.1 μL of ethidium bromide (Applichen
UN2810 1%). Samples were washed three times with
PBS-1% BSA after each step of incubation with anti-
bodies. Four serial dilutions (1/20, 1/40, 1/80, 1/160) of
a pool of positive control plasmas (from healthy adults
with life-long continuous exposure to P. falciparum) and
one dilution (1/20) of five negative control plasmas
(from adults without a history of contact with malaria
parasites) were included in each plate. Samples were
then acquired in a four-colour FACSCalibur (Becton
Dickinson, USA) using CellQuest 3.3 software. Up to
1,000 T-iE (or ethidium bromide positive events) were
counted per sample, and the geometric means (GM) of
the fluorescence intensities were calculated.
Enzyme-linked immunosorbent assay (ELISA)
All plasma samples were assayed for total IgG, isotypes
(IgG1, IgG2, IgG3, IgG4) and IgM against the recombin-
ant proteins MSP-119 (19-kDa C-terminal fragment, 3D7
strain), AMA-1 (ectodomain, 3D7 strain), and EBA-175
(region II, fragment I, CAMP strain) from the ICGEB
(New Delhi, India) [32]. Ninety-six-well plates were
coated with 200 ng per well of antigen diluted in 0.05 M
carbonate-bicarbonate buffer and incubated overnight at
4°C. Next day, plates were blocked with 2% bovine
serum albumin in PBS-Tween for eight hours at 4°C.
Then, plasma samples (dilution 1/200) were added in du-
plicates along with a positive control (a pool of plasmas
from eight adults with lifelong exposure to malaria in the
dilutions: 1/400, 1/800, 1/1,600 and 1/3,200), nine nega-
tive controls (plasmas from nine non-exposed adults, di-
luted 1/400) and two myeloma controls (for conjugated
antibodies) 1 μg/ml and 0.5 μg/ml. All incubations were
followed by three washings with 0.05% Tween 20 + BSA
0.25% in PBS. After one-hour incubation with 100 μL of
peroxidase-conjugated rabbit anti-human IgG (1/8,000),
IgM (1/3,000) (DakoCytomation) and sheep anti-human
IgG1 (1/6,000), IgG2 (1/1,500), IgG3 (1/1,500), IgG4
(1/3,000) isotypes (Binding site, UK) secondary anti-
bodies diluted in wash buffer, respectively, 100 μL of
citric acid 0.243 M +Na2HPO4 0.512 M + 1 mg/ml of
o-phenylenediamine chromogen (Sigma, St Louis, MO,
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for 5 min, and the colorimetric reaction was stopped
with 25 μL of 3 M H2SO4. The specific reactivities of
plasma samples were obtained as optical density (OD)
values (absorbance measured at 492 nm normalized
against a positive control run in every experiment). In
addition, antibody levels were categorized using a cut-
off OD value (the arithmetic mean of negative controls
plus three standard deviations) for statistical analyses.
Parasitaemia
Plasmodium falciparum infections were diagnosed and
quantified by microscopy at 2.5 and 24 months of age, and
in non-programmed visits whenever a child attended the
hospital with fever or history of fever in the preceding
24 hours. Thick and thin blood films were Giemsa-stained
and read as previously described [26]. Cases with sub-
microscopic parasitaemia were assessed by quantitative
real time PCR (qPCR) performed from filter paper blood
spots at birth (from cord blood), 2.5 and 24 months of
age. DNA for qPCR analysis was extracted using the
QIAamp DNA mini kit (Qiagen). The method used for
qPCR was a minor modification of a protocol described
elsewhere [33]. Briefly, the qPCR amplified the multicopy
18S ribosomal RNA gene of P. falciparum. The probe
used was labelled with 6-carboxy-flourescein. A standard
curve was produced using known concentrations of
3D7 strain P. falciparum parasites in parasite culture.
Importing this curve into subsequent qPCR runs achieved
quantification of parasitaemia with an ABI Prism 7500 ap-
paratus (Applied Biosystems).
Definitions and statistical methods
Clinical malaria was defined as axillary temperature
≥37.5°C or reported fever in the preceding 24 hours,
plus positive parasitaemia by microscopy. For anti-VSAs
antibodies the sample fluorescence intensity was defined
as the difference between the GM of the fluorescence
emitted by the T-iE and the GM of the fluorescence
emitted by the non-infected erythrocytes. Antibody
values for ELISA (ELISA - normalized OD values for
total IgG, IgG isotypes and IgM) were logarithmically
transformed and averaged within the groups and pre-
sented as GM plus 95% confidence intervals (CI). Distri-
bution of antibody responses to each antigen at each
cross-sectional visit, acute malaria and convalescence,
are presented as weighted scatter plots. Differences in
antibody prevalence (percentage of positive responders)
between treatment groups at different time points were
estimated by Chi-square and Fisher’s exact test, as ap-
propriate, and differences in continuous antibody values
among treatment groups were evaluated by ANOVA, eval-
uated using a likelihood ratio test and a global p-value was
used for significance. Breadth of antibodies at the cross-sectional visits was defined as the number of antigens
with positive IgG or IgM antibodies responses as de-
fined by the categories above. Mixed-effects linear re-
gression models with a random-intercept at the subject
level were used to analyse factors independently associ-
ated with antibody levels at the cross-sectional visits,
and the variables used to estimate models were: inter-
vention group, age, season (dry/rainy), neighbourhood
(grouped in 10 geographical categories), gender, previ-
ous infection, current infection, low birth weight,
weight for age score, maternal peripheral infection, pla-
cental infection and inflammation, parity, maternal age,
maternal anaemia, congenital infection (parasites in
cord blood by qPCR), use of insecticide-treated nets
(ITN) and documented indoor residual spraying (IRS)
in the household. Selection of the variables for the mul-
tivariable model was done through a forward-stepwise
procedure, where the criterion for including a variable
to the model was p-value ≤0.05 from the likelihood ra-
tio test. In addition, mixed-effects linear regression
models were used to analyse the effect on antibody re-
sponses of the following variables selected for the highest
biological plausibility to influence Ig levels: intervention
group, age, season, neighbourhood, previous infection,
current infection, placental infection and inflammation,
congenital infection and low birth weight. Antibody levels
and breadth of response at the cross-sectional visits in re-
lation to incidence of malaria were assessed by negative
binomial regression models. First, the control group (no
treatment) was evaluated in two risk intervals from 2.5 to
12 months and from 2.5 to 24 months. Second, all treat-
ment groups were assessed in three risk intervals: from
5.5 to 24 months, from 10.5 to 24 months and from 15 to
24 months. The strength of the association between anti-
body levels or breadth and malaria risk was assessed first
unadjusted and second after adjusting by treatment, age,
season, neighbourhood, current infection, previous infec-
tion, maternal infection, congenital infection, placental
inflammation, ITN use and IRS. Statistical significance
was defined at P < 0.05. Crude p values reported in this
exploratory study were not adjusted for multiple com-
parisons and were interpreted for internal coherence,
consistency of results and biological plausibility. Data
analysis was performed using STATA 11 (StataCorp. 2007.
Stata Statistical Software: Release 10. College Station, TX:
StataCorp LP).
Results
Comparison of antibody responses between
chemoprophylaxis groups
The magnitude of antibody responses was compared be-
tween study groups during the intervention period (first
year) and after the intervention period (second year).
Antibody responses to P. falciparum did not differ
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visits (cross-sectionals, first clinical acute episode or
convalescence) for the majority of serological markers
evaluated (Figures 1 and 2). Overall, results of linear re-
gression analyses were similar after adjusting for previ-
ous episodes of clinical malaria.
In the first year of life, significant differences according
to the intervention group were only observed in some
antibody markers at month 10.5. Levels of IgM were
higher in the late exposure and control groups, who
were exposed to infection between months 5.5 and 10.5,
compared to the early exposure group, who were under
chemoprophylaxis during that period (GM, 95% CI;
EBA-175: 0.45, 0.42-0.49 and 0.49, 0.45-0.53 vs 0.42,
0.38-0.46, respectively, p = 0.0469; AMA-1: 0.40, 0.37-
0.43 and 0.40, 0.37-0.42 vs 0.35, 0.32-0.39, p = 0.0543;
MSP-119: 0.43, 0.39-0.47 and 0.46, 0.41-0.52 vs 0.40,
0.36-0.43, p = 0.0885) (Figure 1). Antibody levels did not
differ between groups at month 5.5 following chemo-
prophylaxis in the late exposure group (administered at
months 2.5 to 4.5). Geometric means and 95% CI for
control, late exposure and early exposure groups were:
MSP-119: 0.37, 0.34-041; 0.35, 0.31-0.39 and 0.37, 0.33-
0.41, p = 0.6894; AMA-1: 0.38, 0.34-0.42; 0.33, 0.31-0.37
and 0.37, 0.34-0.41, p = 0.1320; EBA-175: 0.39, 0.35-0.42;
0.35, 032–0.38 and 0.36, 0.33-0.39 p = 0.2106, respectively.
In contrast, IgG levels did not significantly vary after
chemoprophylaxis and thus there was no evidence for
supporting differences in IgG levels between the three
exposure groups at the cross-sectional visits (Figures 2
and 3). This was observed when comparing crude GM
antibody levels, antibody prevalences, and also adjusted
for previous clinical malaria episodes. The only instances
where there were significant differences in IgG responses
between intervention groups was also in the direction of
lower IgG levels after drug administration, and this was
manifested for cytophilic IgGs against MSP-119 at month
10.5. Specifically, the prevalence of positive IgG1 re-
sponses was lower in the early exposure group compared
to the late exposure and control groups (13 vs 28%, 28%,
respectively; Chi2 p = 0.0248), and similarly for levels of
IgG3 (linear regression model unadjusted p = 0.0284, ad-
justed for prior malaria p = 0.0343). Non-cytophilic anti-
bodies (IgG2 and IgG4) yielded consistently low level
responses and are not reported here.
In the second year, no significant differences in antibody
levels were detected overall according to intervention
group. However, children with prior malaria exposure
(documented previous episodes of parasitologically con-
firmed clinical malaria) who had received SP + AS chemo-
prophylaxis any time during year 1 (early exposure and
late exposure groups) had higher IgG to MSP-119, EBA-
175 and AMA-1 at 15 and 24 months of age than Control
children who had been under continuous exposure toP. falciparum (Figures 3, 4 and 5). Regarding IgM re-
sponses, a higher seroprevalence for the early exposure
group compared to the late exposure and control groups
was also observed at age 24 months (MSP-119: 13 vs 7%
and 3%, respectively, p = 0.038; EBA-175: 6 vs 4% and 0%,
p = 0.032; AMA-1: 26 vs 18% and 15%, p = 0.195; Chi2
test).
There were no statistically significant differences in
IgG responses to VSA among the three groups at any of
the sampling visits (Additional file 1).
Analysis of factors affecting the magnitude of antibody
responses
Age was the only factor significantly affecting the level
of all antibodies against all antigens studied, even after
adjusting for all the covariates (Table 1, p < 0.0001 and
Additional file 2). IgM levels significantly increased with
age (Figure 1). Overall, IgG levels were higher at month
2.5 presumably because of the antibodies acquired pas-
sively from the mother, then significantly decayed from
5.5 to 10.5 months, before a gradual increase onwards,
depending on the antigen (Figure 2). Previous and
current infections significantly increased IgG antibodies
and isotypes against the majority of the studied antigens
(p values between <0.0389 and 0.0001). Dry season was
significantly associated with reduced levels of IgG to MSP-
119 and IgG1 to AMA-1 and EBA-175, and with higher
levels of IgG3 to EBA-175 (Table 1, Additional file 2).
Neighbourhood, reflecting heterogeneity in exposure to
malaria infection, influenced levels of IgG, IgG1 and IgG3
mainly against MSP-119 and AMA-1 (Table 1, Additional
file 2). Particular neighbourhoods were consistently associ-
ated with higher antibody responses while other were neu-
tral (Additional files 3 and 4). Other factors examined
related to in utero parasite exposure such as placental in-
fection or inflammation, congenital infection or low birth
weight did not always affect all antibody levels significantly
(Table 1, Additional file 2), but overall, parasite exposure
variables that affected the magnitude of antibodies were
similar between the stepwise and multilevel analyses. Gen-
der and parity did not have an effect on any of the anti-
bodies studied.
Antibody responses during a first acute clinical malaria
episode and at convalescence
Antibody levels significantly varied following a first epi-
sode of clinical malaria compared to the levels measured
at the preceding cross-sectional visits (Table 2). The
most marked increases were observed from acute disease
to convalescence for AMA-1 and MSP-119 responses,
and to a lesser extent for EBA-175 responses. The pat-
tern of cytophilic IgG1 and IgG3 responses before, dur-
ing and after a clinical malaria episode is shown in
Figure 6.
IgM
Figure 1 Weighted scatter plots of IgM levels by cross-sectional visit and treatment group. The area of the symbol is proportional to the
number of observations. Red symbols correspond to IgM levels in those children with previous or current Plasmodium falciparum infection.
Horizontal continuous and dashed lines indicate geometric means at 95% confidence interval.
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IgG
Figure 2 Weighted scatter plots of IgG levels by cross-sectional visit and treatment group. Red symbols correspond to IgG levels in those
children with previous or current Plasmodium falciparum infection.
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IgG
Figure 3 Reverse empirical distribution function of IgG levels by cross-sectional visit and treatment group in children stratified
according to having (dashed line) or not (continuous line) previous episodes of clinical malaria.
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Figure 4 Reverse empirical distribution function of IgG1 levels by cross-sectional visit and treatment group in children stratified
according to having (dashed line) or not (continuous line) previous episodes of clinical malaria.
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IgG3
Figure 5 Reverse empirical distribution function of IgG3 levels by cross-sectional visit and treatment group in children stratified
according to having (dashed line) or not (continuous line) previous episodes of clinical malaria.
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Table 1 Factors independently associated with the
magnitude of antibody response by linear regression
stepwise analysis




IgG MSP-119 Previous infections 1.61 1.41; 1.84 < 0.0001
Current infections 1.39 1.74; 1.64 0.0001
Dry season 0.88 0.80; 0.97 0.0084
AMA-1 Previous infections 1.25 1.12; 1.40 0.0001
Current infections 1.23 1.08; 1.39 0.0019
Dry season 0.90 0.84; 0.97 0.005
EBA-175 Current infections 1.13 1.01; 1.27 0.0389
Congenital infections 1.29 1.10; 1.52 0.0017
IgG1 MSP-119 Previous infections 1.69 1.47; 1.95 0.0001
Current infections 1.31 1.18; 1.68 0.0002
Low birth weight 1.31 1.06; 1.63 0.0143
AMA-1 Previous infections 1.26 1.11; 1.43 0.0003
Current infections 1.29 1.11; 1.49 0.0007
Dry season 0.86 0.79; 0.93 0.0003
Placental infection 1.22 1.04; 1.43 0.0144
Congenital infections 1.31 1.06; 1.62 0.0128
EBA-175 Previous infections 1.13 1.03; 1.59 0.0105
Congenital infections 1.34 1.13; 1.24 0.0008
Dry season 0.88 0.82; 0.95 0.0008
IgG3 MSP-119 Previous infections 1.14 1.06; 1.24 0.0009
Current infections 1.54 1.38; 1.71 <0.0001
Intervention 1.11 1.03; 1.20 0.0068
Congenital infections 1.16 1.03; 1.30 0.0146
AMA-1 Previous infections 1.16 1.04; 1.29 0.0066
Current infections 1.34 1.17; 1.52 <0.0001
Placental
inflammation
1.27 1.06; 1.53 0.0099
EBA-175 Current infections 1.14 1.04; 1.24 0.0008
Dry season 1.10 1.04; 1.16 0.0008
IgM MSP-119 Current infections 1.16 1.09; 1.25 <0.0001
Dry season 1.1 1.05; 1.15 <0.0001
AMA-1 Dry season 0.90 0.86; 0.94 <0.0001
EBA-175 Dry season 1.07 1.03; 1.12 0.0009
Models were adjusted for age and neighbourhood, which were also
significantly associated with antibody levels (p < 0.0006).
1The proportional difference for a particular factor is the ratio between the
average levels of antibodies in children with the factor vs children without the
factor, adjusted for other variables in the model.
2P value using likelihood ratio test.
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Two different sets of analyses were conducted at two
different time risk intervals: from 2.5 months up to
12 months for the control group only, and from
5.5 months up to 24 months for all groups in the threetime periods indicated in Tables 3, 4 and 5 (all children)
and Additional file 5 (only control group). In general, no
significant associations were found between the antibody
levels and subsequent incidence of malaria for both un-
adjusted and adjusted analysis for the majority of anti-
gens. In some cases, there was an association between
higher IgM, IgG and/or IgG1 antibodies to AMA-1 and
MSP-119 and increased incidence of malaria (Tables 3, 4
and 5). The only response significantly associated with
protection was IgG to EBA-175 whereby double amount
of antibodies at 10.5 months correlated with reduced risk
of clinical malaria up to 24 months of age follow up (IRR,
95% CI: 0.67, 0.47-0.94, p = 0.0178, adjusted) (Table 4).
Antibody breadth of response in relation to the incidence
of clinical malaria
Breadth of antibody responses in relation to malaria risk
was determined only for total IgG and IgM against MSP-
119, AMA-1, EBA-175 and VSA in all groups (Table 6)
and just control group (Additional file 6). Overall, there
was an association between higher breadth of response
and higher incidence of clinical malaria (IRR > 1 using 0–1
as reference group), which reached statistical significance
for breadth of IgG responses at 15 months in relation to
risk of malaria up to 24 months of age, in both crude and
adjusted analyses for either all groups or the control
group. The association between higher breadth of re-
sponse and higher incidence of clinical malaria was also
statistically significant at the risk interval between
5.5 months up to 24 months of age when including all
children. The IRR values were higher and the p values
more significant in crude than in the analyses adjusting
for known past/current parasite exposure confounders.
Regarding breadth of IgM antibody responses there was
no statistically significant association in any risk intervals
and group (Table 6, Additional file 6).
Discussion
This study found no evidence to support that the time
of first exposure to blood stage P. falciparum infection,
as controlled by SP + AS anti-malarial chemoprophy-
laxis, has a major influence in the acquisition of anti-
body responses to the MSP-119, AMA-1, EBA-175 and
VSA antigens examined. Consistent with the results of
the clinical trial [26], the development of naturally ac-
quired immunity within the parameters analysed (total
IgM, IgG and subclasses) was not heavily impacted by a
substantial disruption of parasite exposure. Significant
decreases were only observed in IgM and IgG responses
to some antigens in the early exposure group at month
10.5 following chemoprophylaxis, i.e., lower levels of
IgM to EBA-175 and lower levels of positive IgG1 and
IgG3 responses to MSP-119. Thus, IgM to blood stage
antigens at age 10.5 months appeared to be a surrogate
Table 2 Levels of antibodies at the first episode of clinical malaria (acute) and one month later (convalescence) in relation
to the levels of antibodies at the immediately preceding cross-sectional visit (pre-acute) in the three study groups
Antibody Antigen Pre-acute Acute Convalescent
GM1 GM Prop. diff.2 95% CI GM Prop. diff. 95% CI P value3
IgG MSP-119 0.47 0.73 1.56 1.20; 2.02 3.02 6.39 4.86; 8.40 < 0.0001
AMA-1 0.56 0.50 0.88 0.71; 1.09 1.01 1.80 1.44; 2.25 < 0.0001
EBA-175 0.53 0.41 0.77 0.65; 0.91 0.56 1.04 0.87; 1.24 < 0.0013
VSA 17.46 8.60 0.49 0.27; 0.91 11.58 0.64 0.39; 1.06 < 0.0398
IgM MSP-119 0.45 0.68 1.50 1.29; 1.73 0.67 1.47 1.26; 1.72 < 0.0001
AMA-1 0.39 0.44 1.11 0.99; 1.26 0.48 1.23 1.08; 1.39 < 0.0083
EBA-175 0.42 0.49 1.14 1.03; 1.26 0.51 1.18 1.06; 1.31 < 0.0046
IgG1 MSP-119 0.30 0.47 1.54 1.16; 2.04 2.32 7.48 5.54; 10.1 < 0.0001
AMA-1 0.37 0.31 0.82 0.65; 1.04 0.64 1.73 1.35; 2.22 < 0.0001
EBA-175 0.31 0.21 0.69 0.59; 0.81 0.27 0.87 0.74; 1.03 < 0.0001
IgG3 MSP-119 0.11 0.15 1.30 0.99; 1.70 0.49 4.36 3.28; 5.78 < 0.0001
AMA-1 0.14 0.13 0.93 0.77; 1.12 0.29 2.04 1.66; 2.50 < 0.0001
EBA-175 0.11 0.07 0.61 0.52; 0.72 0.09 0.80 0.67; 0.95 < 0.0001
1Geometric means.
2The proportional difference is the ratio between the average levels of antibodies from acute (or convalescent) samples vs the levels from pre-acute samples,
taking into account repeated measures for children.
3P value from Mixed-effects linear regression models using Likelihood Ratio Test.
Figure 6 Weighted scatter plot of antibody levels by type of sample before, during and after a first malaria clinical episode (pre-acu:
pre-acute sample, acu: acute sample, cnv: convalescent sample). The area of the symbol is proportional to the number of observations.
Horizontal continuous and dashed lines indicate geometric means at 95% confidence intervals.
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Table 3 Association between levels of antibodies (two-fold increment) at 5.5 months of age and the incidence of
malaria up to 24 months of age
5.5-24 months
Antigens Antibodies Crude Adjusted
IRR1 95% CI P value2 IRR 95% CI P value
MSP-119 IgG 1.09 0.90; 1.33 0.3783 0.96 0.78; 1.17 0.6853
IgG1 1.10 0.90; 1.33 0.3525 0.96 0.79; 1.17 0.6872
IgG2 1.33 0.72; 2.45 0.3594 1.05 0.61; 1.83 0.8519
IgG3 1.20 0.87; 1.65 0.2508 0.93 0.67; 1.29 0.6599
IgG4 0.66 0.27; 1.60 0.3526 0.48 0.21; 1.14 0.0970
IgM 1.35 0.96; 1.89 0.0768 1.27 0.88; 1.85 0.2013
AMA-1 IgG 2.01 1.58; 2.56 < 0.0001 1.64 1.29; 2.09 < 0.0001
IgG1 1.81 1.48; 2.22 < 0.0001 1.54 1.25; 1.89 < 0.0001
IgG2 1.12 0.75; 1.66 0.5840 0.91 0.61; 1.36 0.6415
IgG3 1.38 1.05; 1.82 0.0169 1.15 0.89; 1.47 0.2803
IgG4 1.27 0.69; 2.33 0.4396 0.94 0.50; 1.78 0.8496
IgM 1.33 0.89; 2.00 0.1590 1.16 0.79; 1.70 0.4468
EBA-175 IgG 1.29 1.04; 1.60 0.0177 1.11 0.90; 1.37 0.3323
IgG1 1.36 1.08; 1.72 0.0077 1.21 0.97; 1.50 0.0916
IgG2 1.21 0.69; 2.12 0.4981 1.21 0.72; 2.04 0.4614
IgG3 1.34 0.97; 1.83 0.0701 1.20 0.89; 1.63 0.2324
IgG4 0.91 0.45; 1.82 0.7837 1.09 0.57; 2.07 0.7936
IgM 1.57 1.04; 2.38 0.0338 1.41 0.94; 2.12 0.0996
VSA IgG 1.42 1.10; 1.84 0.0069 1.55 1.19; 2.01 0.0008
Analysis done by negative binomial regression models adjusted by treatment, season, neighbourhood, current infection, previous infection, maternal infection,
congenital infection, placental inflammation, insecticide-treated bed net use, and indoor residual spraying.
1Incidence rate ratio.
2Negative binomial regression model using likelihood ratio test.
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http://www.malariajournal.com/content/13/1/121of recent P. falciparum exposure. Maternal IgG levels
were high at 2.5 months in all groups before waning
over the first year. The conclusion of this first analysis
was that, overall, a 3–5 month-long drug intervention
had no major impact on P. falciparum-specific IgG
levels in these young infants in face of high levels of ma-
ternal IgG antibodies still circulating in their plasma. Be-
cause of the confounding effect of these passively
transferred antibodies, the impact of the study interven-
tions on IgG levels during the first year of life and the
impact of IgG responses during the first year of life on
subsequent risk of malaria were difficult to ascertain.
Of note, children who received chemoprophylaxis dur-
ing the first year of life and suffered previous malaria in-
fections were characterized by an increase in antibody
levels in the second year, as observed in the stratified cu-
mulative distribution plots (Figures 3, 4 and 5). This pat-
tern appeared to be parallel to the Kaplan Meier survival
curves for cumulative proportion of children with at
least one episode of malaria during the second year of
follow-up, which showed a trend for a higher incidence
of malaria in year 2 in the late and early exposure groupswhen compared to the control group [26]. Thus, these
increased IgG antibody levels in children with docu-
mented parasite exposure reflected the higher incidence
of malaria in the second year in those who received
chemoprophylaxis in the first year. Therefore, antibodies
to these blood stage antigens appeared to be mostly
markers of exposure, and this is consistent with the
strong association between previous or concurrent infec-
tion and IgG levels and breadth demonstrated here and
in previous studies by our group [34,35]. Indeed, data
show that high levels of antibody responses to antigens
such as AMA-1 are commonly associated with greater
future risk of malaria, presumably because children with
increased antibodies levels or breadth are also those who
have suffered more previous episodes of malaria and/or
prenatal parasite exposure, a known and strong risk fac-
tor for subsequent malaria episodes [32,34,36]. This is in
contrast to other studies showing an association between
AMA-1 [3,16,37,38] or MSP-119 [4,16,39] responses and
reduced risk of malaria. Even though, for example, anti-
AMA-1 IgG antibodies are described as some times pro-
tective [3] while other non-protective [40], many studies
Table 4 Association between levels of antibodies (two-fold increment) at 10.5 months of age and the incidence of
malaria up to 24 months of age
10.5-24 months
Antigens Antibodies Crude Adjusted
IRR1 95% CI P value2 IRR 95% CI P value
MSP-119 IgG 1.26 1.03; 1.55 0.0269 1.15 0.94; 1.40 0.1710
IgG1 1.23 1.01; 1.49 0.0385 1.13 0.94; 1.36 0.2081
IgG2 0.82 0.45; 1.49 0.5226 0.76 0.45; 1.27 0.2968
IgG3 1.19 0.77; 1.82 0.4235 0.94 0.63; 1.39 0.7423
IgG4 1.35 0.75; 2.42 0.3096 1.27 0.69; 2.33 0.4361
IgM 0.98 0.65; 1.49 0.9419 1.01 0.70; 1.45 0.9654
AMA-1 IgG 1.86 1.37; 2.53 < 0.0001 1.31 1.00; 1.72 0.0533
IgG1 1.68 1.26; 2.25 0.0002 1.21 0.94; 1.57 0.1366
IgG2 1.12 0.57; 2.23 0.7446 0.98 0.57; 1.67 0.9354
IgG3 1.06 0.71; 1.59 0.7446 0.98 0.71; 1.33 0.8743
IgG4 2.78 1.13; 6.81 0.0261 1.85 0.83; 4.14 0.1360
IgM 1.65 0.94; 2.87 0.0811 2.08 1.26; 3.45 0.0037
EBA-175 IgG 0.73 0.50; 1.09 0.1235 0.67 0.47; 0.94 0.0178
IgG1 0.75 0.50; 1.13 0.1735 0.75 0.54; 1.04 0.0874
IgG2 0.74 0.50; 1.09 0.1124 0.69 0.50; 0.90 0.0239
IgG3 0.90 0.58; 1.40 0.6580 0.80 0.55; 1.17 0.2469
IgG4 0.89 0.56; 1.41 0.6152 0.75 0.49; 1.14 0.1741
IgM 1.12 0.72; 1.74 0.6113 1.48 1.02; 2.14 0.0358
VSA IgG 1.02 0.76; 1.36 0.8827 0.92 0.68; 1.24 0.5864
Analysis done by negative binomial regression models adjusted by treatment, season, neighbourhood, current infection, previous infection, maternal infection,
congenital infection, placental inflammation, insecticide-treated bed net use, and indoor residual spraying.
1Incidence rate ratio.
2Negative binomial regression model using likelihood ratio test.
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http://www.malariajournal.com/content/13/1/121fail to establish any significant association [41]. Dissimi-
larities between reports may be partially related to differ-
ences in age between participants, under two years old
in this study vs older children or adults in other studies.
However, a prominent factor that influence immune cor-
relates analysis is heterogeneity in parasite exposure at
the individual level. The challenges of establishing pro-
tective associations between antibody responses and
malaria susceptibility if prior and present infections are
not registered and taken into account in the analysis are
increasingly being recognized. The only instance in
which there was a protective association between higher
levels of antibodies and reduced incidence of malaria
was for the EBA-175 antigen, and this was mostly shown
after analyses were adjusted for previous malaria epi-
sodes. Since this result has consistently been reproduced
in two other studies in the same area with two different
groups of children [35,42], it is concluded that among the
antigen targets evaluated, EBA-175 is the most promising
blood stage candidate for vaccine development.
Factors affecting the magnitude of anti-malarial anti-
bodies were analysed in detail. Previous studies report thatincreasing age (particularly for AMA-1), heterogeneity of
exposure, proximity to swamps, and higher previous ex-
posure are significant predictors of higher antibody re-
sponses [4,32,35]. In this study, age was also the most
prominent factor significantly influencing the levels of all
antibodies. In addition, factors associated to concurrent or
past parasite exposure, including during gestation and
birth, generally affected antibody levels in these infants.
Season and particular neighbourhoods had increased anti-
body prevalences, however it was not possible to define
the geographic characteristics (e. g., proximity to swamps)
explaining the differences. This study was limited in
that it could not fully evaluate individual heterogeneity
of exposure and differential antibody levels in relation
to geographical parameters influencing malaria trans-
mission intensity.
In these very young children, anti-VSA IgG responses
were not prominent. Levels were very low and dependent
on neighbourhood and age, with an overall pattern show-
ing higher maternally derived IgG waning over time. This
was in contrast to studies in a different endemic area of
Tanzania where the level of antibodies increased with age
Table 5 Association between levels of antibodies (two-fold increment) at 15 months of age and the incidence of
malaria up to 24 months of age
15-24 months
Antigens Antibodies Crude Adjusted
IRR1 95% CI P value2 IRR 95% CI P value
MSP-119 IgG 1.56 1.33; 1.82 < 0.0001 1.29 1.06; 1.57 0.0121
IgG1 1.62 1.39; 1.90 < 0.0001 1.37 1.13; 1.66 0.0011
IgG2 2.14 1.07; 4.27 0.0260 1.37 0.71; 2.28 0.4141
IgG3 1.84 1.36; 2.48 < 0.0001 1.32 0.98; 1.77 0.0591
IgG4 2.22 0.79; 6.21 0.1033 1.35 0.60; 3.05 0.4694
IgM 0.83 0.53; 1.31 0.4290 0.84 0.55; 1.27 0.4027
AMA-1 IgG 1.87 1.52; 2.30 < 0.0001 1.43 1.14; 1.79 0.0023
IgG1 1.96 1.61; 2.38 < 0.0001 1.55 1.27; 1.90 < 0.0001
IgG2 2.32 1.21; 4.44 0.0086 1.89 1.12; 3.20 0.0161
IgG3 1.99 1.48,2.67 < 0.0001 1.41 1.08; 1.83 0.0113
IgG4 2.55 1.24; 5.23 0.0088 1.71 0.95; 3.05 0.0723
IgM 0.78 0.45; 1.37 0.3973 0.64 0.39; 1.04 0.0715
EBA-175 IgG 1.48 1.08; 2.04 0.0141 1.14 0.83; 1.57 0.4052
IgG1 1.78 1.19; 2.68 0.0040 1.31 0.91; 1.89 0.1442
IgG2 0.88 0.42; 1.82 0.7257 0.55 0.27; 1.10 0.0898
IgG3 1.80 1.03; 3.15 0.0283 0.96 0.63; 1.48 0.8697
IgG4 1.40 0.62; 3.17 0.4025 0.98 0.51; 1.89 0.9600
IgM 0.65 0.36; 1.17 0.1510 0.72 0.42; 1.20 0.2133
VSA IgG 1.68 1.18; 2.38 0.0034 1.29 0.94; 1.76 0.1105
Analysis done by negative binomial regression models adjusted by treatment, season, neighbourhood, current infection, previous infection, maternal infection,
congenital infection, placental inflammation, insecticide-treated bed net use, and indoor residual spraying.
1Incidence rate ratio.
2Negative binomial regression model using likelihood ratio test.
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http://www.malariajournal.com/content/13/1/121from five to 24 months [22]. The results of this study do
not support acquisition of VSA IgG by the age of two
years in the Manhiça population at the time of the clinical
trial. There was a lack of association between these anti-
bodies and current malaria infection, in contrast to what
was observed in another study conducted in the same area
at a different time [29], and in Tanzania [22]. This suggests
that in these children, anti-VSA IgG were not involved in
early acquisition of immunity, presumably due to the high
variability of PfEMP-1 antigens and the lower level of ex-
posure during this limited time.
Breadth of antibody response has been suggested to be
an important predictor of protection from clinical mal-
aria in Kenyan children [9], with an inverse association
between increasing breadth of IgG antibody specificities
and risk of malaria, and none of the children who simul-
taneously had high antibody levels to five or more anti-
gens experiencing a clinical episode. Studies assessing
interaction between breadth and risk of malaria are lim-
ited. Here, using only four antigens, a direct association
between breadth of IgG response and subsequent inci-
dence of malaria was either not detected or observed attwo different follow up periods (5.5-24 and 15–24 months
of age), in contrast to the Kenyan study but in the same
line as the relationship between magnitude of antibody re-
sponses and malaria risk. In Manhiça, the association be-
tween IgG antigenic breadth and incidence of malaria was
stronger in the unadjusted analysis and weaker when con-
trolling for variables related to parasite exposure, suggest-
ing that it was highly affected by prior infection but that
we not were able to remove all the confounders. Thus, in
immune correlates analyses in mother-child cohorts it re-
mains a challenge to account for absolute parasite expo-
sures when using a primarily passive surveillance design,
particularly to detect those infections that may be asymp-
tomatic and not accounted for in the adjusted analyses.
Conclusion
The age of first P. falciparum exposure seemed not to
be critical for acquisition of protective immunity as eval-
uated by acquisition of antibody responses to blood
stage antigens that are candidate targets for malaria vac-
cine development. Overall, the breadth and magnitude
of antibody responses were strongly influenced by
Table 6 Association between breadth of antibody response and the incidence of malaria in all chemoprophylactic
groups up to 24 months of age
All groups
Abs1 Time Crude Adjusted
Bth2 N3 IRR4 95% CI P value5 Bth N IRR 95% CI P value
IgG 5.5-24 months 0-1 152 1 - 0.0005 0-1 152 1 - 0.0143
2 47 3.50 1.79; 6.84 2 47 2.64 1.38; 5.06
3 9 3.17 0.82; 12.28 3 9 1.86 0.48; 7.24
10.5-24 months 0-1 189 1 - 0.3412 0-1 189 1 - 0.4438
2 3 4.42 0.39; 49.95 2 3 0.89 0.09; 8.41
3 1 0.85 0.01; 75.19 3 1 11.72 0.29; 504.65
15-24 months 0-1 185 1 - < 0.0001 0-1 185 1 - 0.0297
2 19 8.56 3.68; 19.94 2 19 3.29 1.49; 7.29
3 5 5.42 1.11; 26.52 3 5 2.30 0.55; 9.54
4 1 13.68 0.48; 388.95 4 1 6.14 0.52; 71.92
IgM 5.5-24 months 0 265 1 - 0.9316 0 265 1 - 0.1472
1 23 1.04 1.04; 2.63 1 23 0.50 0.20; 1.26
10.5-24 months 0 246 1 - 0.2402 0 246 1 - 0.6655
1 16 0.40 0.12; 1.35 1 16 1.22 0.41; 3.62
2 4 2.36 0.30; 18.24 2 4 1.91 0.40; 9.11
15-24 months 0 246 1 - 0.8912 0 246 1 - 0.7638
1 14 1.00 0.28; 3.58 1 14 0.58 0.16; 2.09
2 5 2.08 0.29; 15.04 2 5 1.56 0.32; 7.57
3 1 0.97 0.01; 91.36 3 1 0.79 0.03; 19.06
Analysis done by negative binomial regression. All chemoprophylactic groups were assessed in three risk intervals: from 5.5 months to 24 months, from 10.5 to
24 months and from 15.5 to 24 months. The strength of the association between breadth of response and malaria risk was assessed first unadjusted and after
adjusting by treatment, age, season, neighbourhood, current infection, previous infection, maternal infection, congenital infection, placental inflammation,





5Negative binomial regression model using likelihood ratio test.
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http://www.malariajournal.com/content/13/1/121previous exposure and age. Only levels of IgG to EBA-
175 were associated with reduced incidence of malaria
in the second year of life. It remains to be assessed
whether the intervention might have an impact on the
quality of antibody responses such as affinity/avidity, fine
specificity or functionality, and on cellular immune re-
sponses also thought to contribute to naturally acquired
immunity.Additional files
Additional file 1: Comparison of the anti-variant surface antigens
(VSA) Immunoglobulin (Ig) G antibody responses. Differences in
anti-VSA IgG antibodies levels among chemoprophylaxis groups, at the
five sampling study visits; assessed by ANOVA.
Additional file 2: Variables associated to antibody levels assessed
by multilevel regression model. Analyse of variables associated with
antibody levels assessed by mixed-effects linear regression models
including the following variables: intervention group, age, season,neighbourhood, previous infection, current infection, low birth weight,
placental infection, placental inflammation and congenital infection.
Additional file 3: Association between different neighborhoods and
antibody levels. Proportional differences and P-values of the association
between neighbourhood and the magnitude of antibody response by
linear regression analysis.
Additional file 4: District map of the Manhiça study area. Group of
study regions and distribution of study participants per neighbourhood
(bairros).
Additional file 5: Magnitude of antibody response related to
incidence of clinical malaria only in control group. Association
between levels of antibodies (2-fold increment) at 2.5 months of age and
the incidence of malaria up to 12 and 24 months of age, only for the
placebo control group. Analysis done by negative binomial regression
models adjusted by season, neighborhood, current infection, previous
infection, maternal infection, congenital infection, placental inflammation,
insecticide treated bednet use and indoor residual spraying.
Additional file 6: Breadth of antibody response related to incidence
of clinical malaria only in control group. Analysis done by negative
binomial regression. Participants of control group were assessed in five
risk intervals: from 2.5 months to 12 months, from 2.5 months to
24 months, from 5.5 months to 24 months, from 10.5 to 24 months and
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http://www.malariajournal.com/content/13/1/121from 15.5 to 24 months. The strength of the association between
breadth of response and malaria risk was assessed first unadjusted and
after adjusting by treatment, age, season, neighbourhood, current
infection, previous infection, maternal infection, congenital infection,
placental inflammation, insecticide treated bednet use and indoor
residual spraying.
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